Ascendis Pharma A/S
ASND
$191.08
-$4.90-2.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 44.58% | 32.53% | 21.33% | 27.68% | 16.30% |
| Total Depreciation and Amortization | -4.24% | -6.68% | -6.36% | -0.76% | 4.36% |
| Total Amortization of Deferred Charges | -4.27% | -4.27% | -4.27% | 14.61% | 14.61% |
| Total Other Non-Cash Items | -54.51% | -48.19% | 68.10% | 90.91% | 212.93% |
| Change in Net Operating Assets | 76.59% | 102.78% | -4.59% | 73.14% | -188.77% |
| Cash from Operations | 50.23% | 48.59% | 34.58% | 53.10% | 37.10% |
| Capital Expenditure | -319.56% | -22.09% | 41.54% | 84.34% | 81.85% |
| Sale of Property, Plant, and Equipment | -100.00% | 1,742.34% | 1,742.34% | 1,951.70% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.01% | -100.00% | -97.43% | -95.10% | -86.54% |
| Cash from Investing | -116.66% | -101.16% | -97.58% | -95.00% | -86.31% |
| Total Debt Issued | -1.54% | -1.54% | -1.54% | -6.55% | -- |
| Total Debt Repaid | -30.60% | -9.28% | -8.88% | -17.62% | -32.39% |
| Issuance of Common Stock | 1,058.78% | 1,024.07% | 3,209.62% | 2,708.56% | 355.30% |
| Repurchase of Common Stock | -1,488.96% | -1,488.96% | -- | -90,500.00% | -90,500.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 175.33% | 168.79% | 233.57% | 212.19% | 8,594.83% |
| Foreign Exchange rate Adjustments | -349.08% | 118.57% | 481.38% | 69.84% | 169.97% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 279.51% | 213.57% | 427.56% | 219.93% | 49.24% |